SCHEMBL18271802

SCHEMBL18271802

CCCC(C=O)CC(=O)OC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CTSK P43235 5/20 0.37
HSD17B10 Q99714 2/20 0.33
POLB P06746 1/20 0.33
POLA1 P09884 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
HDAC9 Q9UKV0 1/20 0.33
HDAC5 Q9UQL6 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
MGAM O43451 1/20 0.33
GAA P10253 1/20 0.33
SI P14410 1/20 0.33
MGAM2 Q2M2H8 1/20 0.33
BIRC2 Q13490 1/20 0.33
TET2 Q6N021 1/20 0.32
CHRM1 P11229 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19439578 0.89 TSHR (0.53) TSHRSMN1; SMN2CTSKHSD17B10POLB
SCHEMBL28996869 0.85 ZDHHC7 (0.46) TSHRSMN1; SMN2HSD17B10POLBPOLA1
SCHEMBL2137700 0.83 TSHR (0.40) TSHRSMN1; SMN2CTSKHSD17B10POLB
SCHEMBL17759039 0.82 MGAM (0.41) TSHRSMN1; SMN2CTSKHSD17B10POLB
SCHEMBL17755804 0.82 TSHR (0.34) TSHRHSD17B10MGAMGAASI
SCHEMBL29004671 0.82 TSHR (0.44) TSHRSMN1; SMN2CTSKPOLBPOLA1
SCHEMBL27163541 0.82 ALDH1A1 (0.35) TSHRHSD17B10POLBPOLA1HDAC7
SCHEMBL17759040 0.81 LMNA (0.43) TSHRSMN1; SMN2CTSKCHRM1AKR1A1
SCHEMBL9442266 0.79 TSHR (0.48) TSHRSMN1; SMN2POLBPOLA1MEN1
SCHEMBL17759195 0.79 HDAC3 (0.40) TSHRSMN1; SMN2CTSKHDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11673862-B2 Processes to produce brivaracetam SUZHOU PENGXU PHARMATECH CO. LTD. (CN) 2023-06-13 US disclosed
US-20180155284-A1 PROCESSES TO PRODUCE BRIVARACETAM ESTEVE QUIMlCA S.A. (ES) 2018-06-07 US disclosed
WO-2016191435-A1 PROCESSES TO PRODUCE BRIVARACETAM WANG PENG (US) 2016-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11673862-B2 Processes to produce brivaracetam BLVRB, CYP3A4, POR TSHR 1088/4885SMN1; SMN2 4495/4885CTSK 3252/4885
US-20180155284-A1 PROCESSES TO PRODUCE BRIVARACETAM BLVRB, CYP3A4, POR TSHR 1088/4885SMN1; SMN2 4495/4885CTSK 3252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.